IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: I. Luttichuys who wrote (285)	1/14/1997 11:23:00 PM
From: Don Cheng	of 1762

Hi Bennett, just want to add one comment to see if you agree with it. This is regarding the posting from Greg. CNTO started to develop the anti-CD4 mab a few years ago. The problem that they had was a significant high percentage of HAMA/HACA response from patients treated with their product. I believe they have been trying to solve this problem since then. I have not heard any HAMA/HACA problem on IDPH's CE9.1 because it is a primatized antibody. I believe that this could be a big advantage for CE9.1 in the market. I don't know if CNTO has resolved this issue yet. I am also interested in another bioteh company, BTGC. I am wondering if you are interested in moveing to the BTGC thread and discuss their products. It is a very exciting company with two approved drugs and a rich pipeline. Don

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next